Polar Asset Management Partners Inc. Has $295,000 Holdings in Repligen Corporation $RGEN

Key Points

• Polar Asset Management Partners Inc. reduced its holdings in Repligen Corporation by 66.4%, now owning 2,318 shares valued at approximately $295,000.
• Several institutional investors have increased or acquired stakes in Repligen, with 97.64% of the stock being owned by these investors.
• Repligen Corporation reported a quarterly earnings miss with $0.37 EPS, below the consensus estimate of $0.40, despite a 14.8% year-over-year revenue increase to $182.37 million.

Polar Asset Management Partners Inc. lowered its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 66.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,318 shares of the biotechnology company's stock after selling 4,582 shares during the period. Polar Asset Management Partners Inc.'s holdings in Repligen were worth $295,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of RGEN. Raiffeisen Bank International AG bought a new position in shares of Repligen in the fourth quarter valued at approximately $29,000. Twin Tree Management LP bought a new position in shares of Repligen in the first quarter valued at approximately $29,000. Signaturefd LLC raised its stake in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 128 shares during the last quarter. Center for Financial Planning Inc. raised its stake in shares of Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 193 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in shares of Repligen by 99.4% in the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 332 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on RGEN. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a research note on Tuesday, July 22nd. Barclays initiated coverage on shares of Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective for the company. Evercore ISI dropped their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $169.55.

Repligen Stock Up 1.3%

RGEN stock traded up $1.54 during trading hours on Wednesday, reaching $120.23. 986,487 shares of the stock were exchanged, compared to its average volume of 775,657. The firm's 50-day moving average is $121.30 and its 200-day moving average is $128.72. The company has a market cap of $6.76 billion, a price-to-earnings ratio of -480.90, a PEG ratio of 2.22 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the prior year, the company earned $0.40 earnings per share. The company's quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the business's stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.